<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2026">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134792</url>
  </required_header>
  <id_info>
    <org_study_id>Pt 2221</org_study_id>
    <nct_id>NCT05134792</nct_id>
  </id_info>
  <brief_title>Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients</brief_title>
  <official_title>Effect of Pre-emptive Intravenous Immunoglobulin Administration on the Incidence of Septic Episodes in Pediatric Burn Patients: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of pre-emptive intravenous immunoglobulin administration on the incidence of septic&#xD;
      episodes in pediatric burn patients: A randomized controlled study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After randomization, Treatment and control groups will receive Parkland formula (4 ml/kg per&#xD;
      percent total burn surface area; (TBSA), counting moderate (partial thickness) and severe&#xD;
      (full thickness) burn area only) using Ringer's lactate solution (half of the fluid will be&#xD;
      given over the first eight hours and the remaining half will be given over the next 16&#xD;
      hours), plus normal 24-hour maintenance fluid requirements using glucose solution.&#xD;
&#xD;
      When initiating Parkland, treatment group (Group A) will receive intravenous immunoglobulin&#xD;
      IVIG (LIV-GAMMA &quot;S/D treated Human Immunoglobulin&quot; 2.5 grams/50 ml) with a dose of 200 mg/kg&#xD;
      once on admission.&#xD;
&#xD;
        -  On each septic or septic shock episode in either groups, the patients will be treated&#xD;
           with appropriate antibiotics empirically or culture-based.&#xD;
&#xD;
             -  Assessments&#xD;
&#xD;
             -  On admission, all patients included in the study will be fully examined clinically&#xD;
                to identify the extent and area of burn and clinical signs of infection or&#xD;
                dehydration as fever, respiratory rate, urinary output and capillary refill.&#xD;
                Besides, non-invasive blood pressure (systolic blood pressure (SBP), diastolic&#xD;
                blood pressure (DBP) and mean arterial blood pressure (MAP)), electrocardiogram and&#xD;
                arterial oxygen saturation will be assessed.&#xD;
&#xD;
             -  Parameters to be measured&#xD;
&#xD;
        -  Serum immunoglobulin G( IgG) level,&#xD;
&#xD;
        -  Serum micro RNA (miR-25) level,&#xD;
&#xD;
        -  Serum C reactive protein (CRP) level,&#xD;
&#xD;
        -  Serum lactate,&#xD;
&#xD;
        -  Serum Procalcitonin • In addition, Complete Blood picture with differential, coagulation&#xD;
           profile, liver function tests (alanine transaminase (ALT), aspartate amino&#xD;
           transferase(AST), Albumin and Bilirubin), and kidney functions (Blood urea nitrogen&#xD;
           (BUN) and serum creatinine) will be evaluated.&#xD;
&#xD;
      Pan cultures (blood with/without wound culture, throat swab or sputum culture and urinary&#xD;
      analysis and culture), will be withdrawn for baseline readings and redrawn if any signs of&#xD;
      systemic inflammatory response,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of sepsis during one week of ICU stay will be recorded.</measure>
    <time_frame>one week</time_frame>
    <description>Sepsis is defined by clinical criteria (temperature more than 38.9 °C, leukocytosis, thrombocytopenia, glucose intolerance, and/or new onset of ileus) and/or the presence of a positive blood culture in association with clinical signs of infection/sepsis. An increase in C-reactive protein level will be also used as an early laboratory marker for sepsis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of septic shock</measure>
    <time_frame>one week</time_frame>
    <description>Defined by evidence of sepsis as previously mentioned and need for inotropes to support circulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographic data as Age</measure>
    <time_frame>Baseline</time_frame>
    <description>In years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographic data as Sex</measure>
    <time_frame>Baseline</time_frame>
    <description>sex of the study candidate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Demographic data as total body surface area</measure>
    <time_frame>Baseline</time_frame>
    <description>Total body surface area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of burn injured area</measure>
    <time_frame>Baseline</time_frame>
    <description>Whether first ,second or third degree burn.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic data as heart rate</measure>
    <time_frame>one week</time_frame>
    <description>Heart rate in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic data as oxygen saturation</measure>
    <time_frame>one week</time_frame>
    <description>oxygen saturation in percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic data as body temperature.</measure>
    <time_frame>One week</time_frame>
    <description>body temperature in degrees Celsius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic data as systolic ,diastolic and mean non invasive blood pressure.</measure>
    <time_frame>one week</time_frame>
    <description>Systolic ,Diastolic and mean non invasive blood pressure in mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEdiatric Logistic Organ Dysfunction score 2 (PELOD-2)</measure>
    <time_frame>One week</time_frame>
    <description>Clinical assessment score used as diagnostic and prognostic tool of sepsis in pediatrics.It includes cardiovascular, neurologic, respiratory, hematologic, renal dysfunctions assessment adjusted to age.A higher PELOD-2 score correlates with a higher number of organ failures and mortality rate incidence.Each measurement gives a score form 0 to 6 and total score is directly proportional to increased morbidity and mortality probability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>serum Procalcitonin</measure>
    <time_frame>Day 1 ,Day3 ,Day 7 and on each incidence of sepsis, assessed up to 30 days.</time_frame>
    <description>ng/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>serum IgG</measure>
    <time_frame>Day 1,Day 3 ,Day 7.</time_frame>
    <description>g/L.</description>
  </other_outcome>
  <other_outcome>
    <measure>serum C-reactive protein</measure>
    <time_frame>Day 1 ,Day3 ,Day 7 and on each incidence of sepsis, assessed up to 30 days.</time_frame>
    <description>mg/L.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Burn Shock</condition>
  <arm_group>
    <arm_group_label>No intravenous immunoglobulin (IVIG)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group are burn patients with inclusion criteria that did not receive IVIG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous immunoglobulin (IVIG) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pediatric burn patients between 1and 5 years with 10% or greater burn area of TBSA within 24 hours of onset of burn will receive intravenous immunoglobulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immunoglobulin</intervention_name>
    <description>All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 150 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.</description>
    <arm_group_label>Intravenous immunoglobulin (IVIG) group</arm_group_label>
    <other_name>LIV GAMMA &quot;S/D treated Human Immunoglobulin &quot;2.5 grams/50 ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All burn patients 1 to 5 years old with 10% or greater burn area of TBSA .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with septic shock (evidence of infection and inotropes) .&#xD;
&#xD;
          -  Burns more than 48 hours duration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanan Mostafa</last_name>
    <role>Principal Investigator</role>
    <affiliation>lecturer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanan Mostafa, MD</last_name>
    <phone>1110199988</phone>
    <email>hanan.mostafa@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Lotfy, MD+</last_name>
      <phone>+201000608905</phone>
      <email>ahmed.lotfy@kasralainy.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Galal NM. Pattern of intravenous immunoglobulins (IVIG) use in a pediatric intensive care facility in a resource limited setting. Afr Health Sci. 2013 Jun;13(2):261-5. doi: 10.4314/ahs.v13i2.9.</citation>
    <PMID>24235922</PMID>
  </results_reference>
  <results_reference>
    <citation>Lyons JM, Davis C, Rieman MT, Kopcha R, Phan H, Greenhalgh D, Palmieri T, Kagan R. Prophylactic intravenous immune globulin and polymixin B decrease the incidence of septic episodes and hospital length of stay in severely burned children. J Burn Care Res. 2006 Nov-Dec;27(6):813-8.</citation>
    <PMID>17091076</PMID>
  </results_reference>
  <results_reference>
    <citation>Munster AM, Hoagland HC, Pruitt BA Jr. The effect of thermal injury on serum immunoglobulins. Ann Surg. 1970 Dec;172(6):965-9.</citation>
    <PMID>5496482</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Hanan Mostafa ,MD</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia ,surgical intensive care and Pain .</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

